Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
In the face of a frothy market, Jim Cramer encourages investors to stay the course, highlighting numerous positive stock narratives that counterbalance the market's irrationality.
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 3.2% in the afternoon session after the stock extended its positive momentum partly fueled by reports of major insider buying by top executives, including the CEO, which is often seen as a strong vote of confidence. Additionally, news that the company has signed a multi-billion dollar deal with an AI health tech company (Superluminal) to discover and develop new obesity medicines also contributed to the positive sentiment. Finally, the company's decision to increase the price of its popular diabetes and weight-loss drug Mounjaro in the UK, in response to US political pressure, was also seen as a positive for future revenue.
Major tech-heavy indices edged lower from record highs by midday Friday in New York, as investors adopted a cautious stance ahead of the Trump-Putin meeting and after data showed a dip in consumer confidence alongside mounting inflation concerns.
Several companies, including Palantir and Eli Lilly, have raised guidance, reflecting positivity surrounding their results. Let’s take a closer look at what drove the strong quarters.
Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic diseases.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 7.7%. This drop is a noticeable divergence from the S&P 500’s 5.5% return.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session.
LLY has given back meaningful ground over recent horizons: the stock is down approximately $103.94 (≈-13.6%) month-to-date and about $119.68 (≈-15.4%) year-to-date.
Eli Lilly will raise Mounjaro's UK price by 170% in September while launching its Kwikpen injector in India, intensifying competition with Novo Nordisk in the global obesity drug market.
